High-Density Lipoprotein as a New Target for Leprosy Therapy
- 25 September 2020
- journal article
- editorial
- Published by Taylor & Francis in Future Microbiology
- Vol. 15 (13) , 1197-1199
Abstract
No abstract availableKeywords
Funding Information
- Strategic Research in Health (PAPES VI)- FIOCRUZ
- National Council for Scientific and Technological Development-CNPq
This publication has 17 references indexed in Scilit:
- Effects of serum amyloid A on the structure and antioxidant ability of high-density lipoproteinBioscience Reports, 2016
- Regulation of HDL Genes: Transcriptional, Posttranscriptional, and Posttranslational2014
- Statins Increase Rifampin Mycobactericidal EffectAntimicrobial Agents and Chemotherapy, 2014
- Mycobacterium lepraeintracellular survival relies on cholesterol accumulation in infected macrophages: a potential target for new drugs for leprosy treatmentCellular Microbiology, 2014
- Metabonomics Reveals Drastic Changes in Anti-Inflammatory/Pro-Resolving Polyunsaturated Fatty Acids-Derived Lipid Mediators in Leprosy DiseasePLOS Neglected Tropical Diseases, 2013
- Regulation of the expression of key genes involved in HDL metabolism by unsaturated fatty acidsBritish Journal of Nutrition, 2012
- Modifying Apolipoprotein A-I by Malondialdehyde, but Not by an Array of Other Reactive Carbonyls, Blocks Cholesterol Efflux by the ABCA1 PathwayJournal of Biological Chemistry, 2010
- Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosyJournal of Clinical Investigation, 2008
- A study of oxidative stress in paucibacillary and multibacillary leprosyIndian Journal of Dermatology, Venereology and Leprology, 2008
- Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-IJournal of Clinical Investigation, 2001